• Concizumab ELISA Kit
1 1

AntibodySystem

KDC82802

Concizumab ELISA Kit

Concizumab ELISA Kit

Title

Catalog No.: KDC82802

Catalog No. KDC82802
Product name Concizumab ELISA Kit
Size 96 T
Description PRINCIPLE OF THE ASSAY This assay employs the quantitative indirect enzyme immunoassay technique. Human TFPI has been pre-coated onto a microplate. Standards or samples are pipetted into the wells and any Concizumab present is bound by the immobilized protein. After washing away any unbound substances, a biotin-labeled Mouse Anti-Human IgG antibody is added to the wells. After washing away any unbound substances, Streptavidin-HRP is added to the wells. Following a wash to remove any unbound enzyme reagent, a substrate solution is added to the wells and color develops in proportion to the amount of Concizumab bound in the initial step. The color development is stopped and the intensity of the color is measured.
Applications Used for the quantitative determination of Concizumab concentration in serum and plasma.
Stability and Storage When the kit was stored at the recommended temperature for 6 months, the signal intensity decreased by less than 20%.
Detection method Colorimetric
Precision CV<15%
Sample type Plasma, Serum
Assay type Quantitative
Sensitivity 3.58 ng/mL
Range 6.25 - 200 ng/mL
Recovery 80-120%
Background Concizumab (mAb 2021) is a high-affinity, humanized, monoclonal IgG4 antibody (mAb) developed by Novo Nordisk A/S. It was directed against the Kunitz-2 domain of human tissue factor (TF) pathway inhibitor (TFPI), designed to target and selectively block the factor X (FX) a (FXa) binding site of TFPI. As a mAb, concizumab has the advantage of being administered subcutaneously, and exhibits good solubility and stability, allowing administration as a liquid formulation via a ready- and easy-to-use portable pen device. Phase 2 trials of concizumab are ongoing for Haemophilia A and B. On 12 October 2017, orphan designation (EU/3/17/1940) was granted by the European Commission to Novo Nordisk A/S, Denmark, for concizumab for the treatment of haemophilia B.
Alternative Names Anti-TFPI, NN7415, mab2021, CAS: 1312299-39-0
Shipping 2-8 ℃
Note For Research Use Only.
전체 세부 정보 보기